A prediction model based on biomarkers and clinical characteristics for detection of lung cancer in pulmonary nodules

Translational Oncology

Volumn 10, Issue 1, 2017, Pages 40-45

  Ma, Jie ^a,b   Guarnera, Maria A ^b   Zhou, Wenxian ^c   Fang, HongBin ^c   Jiang, Feng ^b  

^a JIANGSU UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 19B 3P; MICRORNA 29B 3P; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING;

EID: 85011928243     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2016.11.001     Document Type: Article

References (24)

1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, and Sicks JD (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365, 395–409.
2. Moyer VA (2014). Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160, 330–338.
3. Diederich S and Das M (2006). Solitary pulmonary nodule: detection and management. Cancer Imaging 6, S42–S46.
4. Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, and Gohagan JK, et al (2011). The National Lung Screening Trial: overview and study design. Radiology 258, 243–253.
5. Patz Jr EF, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, Chiles C, Black WC, and Aberle DR (2014). Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 174, 269–274.
6. Melief CJ and Finn OJ (2011). Cancer immunology. Curr Opin Immunol 23, 234–236.
7. Bluth M, Lin YY, Zhang H, Viterbo D, and Zenilman M (2008). Use of gene expression profiles in cells of peripheral blood to identify new molecular markers of acute pancreatitis. Arch Surg 143, 227–233.
8. Baine MJ, Chakraborty S, Smith LM, Mallya K, Sasson AR, Brand RE, and Batra SK (2011). Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One 6, e17014.
9. Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, and Dorner AJ, et al (2003). Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 63, 6069–6075.
10. Croce CM and Calin GA (2005). miRNAs, cancer, and stem cell division. Cell 122, 6–7.
11. Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola FM, and Wang E, et al (2010). miR-17-92 expression in differentiated T cells — implications for cancer immunotherapy. J Transl Med 8, 17.
12. Ma J, Lin Y, Zhan M, Mann DL, Stass SA, and Jiang F (2015). Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer. Lab Investig 95, 1197–1206.
13. Wang WS, Liu LX, Li GP, Chen Y, Li CY, Jin DY, and Wang XL (2013). Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev Res (Phila) 6, 331–338.
14. Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, and Edell ES (1997). The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 157, 849–855.
15. Gould MK, Ananth L, and Barnett PG (2007). A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest 131, 383–388.
16. Schultz EM, Sanders GD, Trotter PR, Patz Jr EF, Silvestri GA, Owens DK, and Gould MK (2008). Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax 63, 335–341.
17. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, Yasufuku K, Martel S, Laberge F, and Gingras M, et al (2013). Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 369, 910–919.
18. Li Y, Chen KZ, and Wang J (2011). Development and validation of a clinical prediction model to estimate the probability of malignancy in solitary pulmonary nodules in Chinese people. Clin Lung Cancer 12, 313–319.
19. Lin H, Zhong WZ, Yang XN, Zhang XC, Yang JJ, Zhou Q, Yan HH, Liao RQ, Nie Q, and Dong S, et al (2012). A clinical model to estimate the pretest probability of lung cancer, based on 1198 pedigrees in China. J Thorac Oncol 7, 1534–1540.
20. MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, Patz Jr EF, and Swensen SJ (2005). Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 237, 395–400.
21. Hanley JA and McNeil BJ (1983). A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148, 839–843.
22. Goulart BH and Ramsey SD (2013). Lung cancer screening with low-dose computed tomography. J Natl Compr Cancer Netw 11, 366–367.
23. Toloza EM, Harpole L, and McCrory DC (2003). Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 123, 137S–146S.
24. Nolen BM, Lomakin A, Marrangoni A, Velikokhatnaya L, Prosser D, and Lokshin AE (2015). Urinary protein biomarkers in the early detection of lung cancer. Cancer Prev Res (Phila) 8, 111–119.